Review





Similar Products

anti h  (ATCC)
96
ATCC anti h
Anti H, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti h/product/ATCC
Average 96 stars, based on 1 article reviews
anti h - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

93
Vector Laboratories succinylated wheat germ agglutinin agarose beads
A Protein levels of OGT, OGA and O-GlcNAc in bone-metastatic H460-BM subline and parental H460 cells. Blots are representative of three independent experiments. B Schematic of pulldown strategy to identify O-GlcNAc-modified proteins contributing to enhanced bone metastasis in H460-BM cells. C Left, significantly enriched ( p < 0.05) biological processes (GO analysis) for O-GlcNAc-modified proteins in H460-BM cells (top 10 pathways shown). Right, Enrichment of O-GlcNAcylation nucleoporins identified by mass spectrometry. D O-GlcNAcylation protein levels of POM121 in bone-metastatic H460-BM subline and parental H460 cells. O-GlcNAcylated proteins were pulled down using <t>sWGA-beads.</t> Blots are representative of three independent experiments. E H460-BM cells expressing Myc (tag)-POM121 were treated with or without OGA inhibitor Thiamet G (TMG, 10 mM, 24 h). GlcNAc (+) indicates that sWGA-beads were pre-blocked with GlcNAc (500 mM, 24 h) prior to pulldown. Immunoprecipitation (IP) and immunoblots (IB) were performed using the indicated antibodies. Data are representative of three independent experiments. F H460-BM cells expressing Myc (tag)-POM121 and mutations were subjected to sWGA-beads pulldown or anti-Myc (tag)-IP. Immunoblots identified Ser199 as an O-GlcNAc modification site. Data are representative of three independent experiments. G Mapping the O-GlcNAcylated residue Ser199 on POM121 by liquid chromatography-tandem mass spectrometry (LC-MS/MS). H , I O-GlcNAcylation of POM121 at the Ser199 site in NSCLC promotes bone metastasis in nude mouse model. H Bioluminescence imaging of nude mice four weeks after intracardiac injection of H460-BM or H460-BM POM121-S199A cells (1 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document} × 10 5 cells/mouse). Data are represented as mean ± SEM; n = 6 mice/group, *** p < 0.001, unpaired t-test. I Representative H&E staining and tumor area quantifications of bone metastasis sections from mice in ( H ). Dashed lines demarcate tumor boundaries. Scale bar, 20 µm. Data are represented as mean ± SEM; **** p < 0.0001, unpaired t-test.
Succinylated Wheat Germ Agglutinin Agarose Beads, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/succinylated wheat germ agglutinin agarose beads/product/Vector Laboratories
Average 93 stars, based on 1 article reviews
succinylated wheat germ agglutinin agarose beads - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

99
MedChemExpress anti keap1 affinity protein a g magnetic beads 565 jo urn al pr pr oo f
A Protein levels of OGT, OGA and O-GlcNAc in bone-metastatic H460-BM subline and parental H460 cells. Blots are representative of three independent experiments. B Schematic of pulldown strategy to identify O-GlcNAc-modified proteins contributing to enhanced bone metastasis in H460-BM cells. C Left, significantly enriched ( p < 0.05) biological processes (GO analysis) for O-GlcNAc-modified proteins in H460-BM cells (top 10 pathways shown). Right, Enrichment of O-GlcNAcylation nucleoporins identified by mass spectrometry. D O-GlcNAcylation protein levels of POM121 in bone-metastatic H460-BM subline and parental H460 cells. O-GlcNAcylated proteins were pulled down using <t>sWGA-beads.</t> Blots are representative of three independent experiments. E H460-BM cells expressing Myc (tag)-POM121 were treated with or without OGA inhibitor Thiamet G (TMG, 10 mM, 24 h). GlcNAc (+) indicates that sWGA-beads were pre-blocked with GlcNAc (500 mM, 24 h) prior to pulldown. Immunoprecipitation (IP) and immunoblots (IB) were performed using the indicated antibodies. Data are representative of three independent experiments. F H460-BM cells expressing Myc (tag)-POM121 and mutations were subjected to sWGA-beads pulldown or anti-Myc (tag)-IP. Immunoblots identified Ser199 as an O-GlcNAc modification site. Data are representative of three independent experiments. G Mapping the O-GlcNAcylated residue Ser199 on POM121 by liquid chromatography-tandem mass spectrometry (LC-MS/MS). H , I O-GlcNAcylation of POM121 at the Ser199 site in NSCLC promotes bone metastasis in nude mouse model. H Bioluminescence imaging of nude mice four weeks after intracardiac injection of H460-BM or H460-BM POM121-S199A cells (1 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document} × 10 5 cells/mouse). Data are represented as mean ± SEM; n = 6 mice/group, *** p < 0.001, unpaired t-test. I Representative H&E staining and tumor area quantifications of bone metastasis sections from mice in ( H ). Dashed lines demarcate tumor boundaries. Scale bar, 20 µm. Data are represented as mean ± SEM; **** p < 0.0001, unpaired t-test.
Anti Keap1 Affinity Protein A G Magnetic Beads 565 Jo Urn Al Pr Pr Oo F, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti keap1 affinity protein a g magnetic beads 565 jo urn al pr pr oo f/product/MedChemExpress
Average 99 stars, based on 1 article reviews
anti keap1 affinity protein a g magnetic beads 565 jo urn al pr pr oo f - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

95
Proteintech recombinant 176 jo urn al pr e p roo f
A Protein levels of OGT, OGA and O-GlcNAc in bone-metastatic H460-BM subline and parental H460 cells. Blots are representative of three independent experiments. B Schematic of pulldown strategy to identify O-GlcNAc-modified proteins contributing to enhanced bone metastasis in H460-BM cells. C Left, significantly enriched ( p < 0.05) biological processes (GO analysis) for O-GlcNAc-modified proteins in H460-BM cells (top 10 pathways shown). Right, Enrichment of O-GlcNAcylation nucleoporins identified by mass spectrometry. D O-GlcNAcylation protein levels of POM121 in bone-metastatic H460-BM subline and parental H460 cells. O-GlcNAcylated proteins were pulled down using <t>sWGA-beads.</t> Blots are representative of three independent experiments. E H460-BM cells expressing Myc (tag)-POM121 were treated with or without OGA inhibitor Thiamet G (TMG, 10 mM, 24 h). GlcNAc (+) indicates that sWGA-beads were pre-blocked with GlcNAc (500 mM, 24 h) prior to pulldown. Immunoprecipitation (IP) and immunoblots (IB) were performed using the indicated antibodies. Data are representative of three independent experiments. F H460-BM cells expressing Myc (tag)-POM121 and mutations were subjected to sWGA-beads pulldown or anti-Myc (tag)-IP. Immunoblots identified Ser199 as an O-GlcNAc modification site. Data are representative of three independent experiments. G Mapping the O-GlcNAcylated residue Ser199 on POM121 by liquid chromatography-tandem mass spectrometry (LC-MS/MS). H , I O-GlcNAcylation of POM121 at the Ser199 site in NSCLC promotes bone metastasis in nude mouse model. H Bioluminescence imaging of nude mice four weeks after intracardiac injection of H460-BM or H460-BM POM121-S199A cells (1 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document} × 10 5 cells/mouse). Data are represented as mean ± SEM; n = 6 mice/group, *** p < 0.001, unpaired t-test. I Representative H&E staining and tumor area quantifications of bone metastasis sections from mice in ( H ). Dashed lines demarcate tumor boundaries. Scale bar, 20 µm. Data are represented as mean ± SEM; **** p < 0.0001, unpaired t-test.
Recombinant 176 Jo Urn Al Pr E P Roo F, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant 176 jo urn al pr e p roo f/product/Proteintech
Average 95 stars, based on 1 article reviews
recombinant 176 jo urn al pr e p roo f - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

96
Bethyl goat anti 451 jo urn al pr e p ro f 22 mouse fitc conjugated antibody
A Protein levels of OGT, OGA and O-GlcNAc in bone-metastatic H460-BM subline and parental H460 cells. Blots are representative of three independent experiments. B Schematic of pulldown strategy to identify O-GlcNAc-modified proteins contributing to enhanced bone metastasis in H460-BM cells. C Left, significantly enriched ( p < 0.05) biological processes (GO analysis) for O-GlcNAc-modified proteins in H460-BM cells (top 10 pathways shown). Right, Enrichment of O-GlcNAcylation nucleoporins identified by mass spectrometry. D O-GlcNAcylation protein levels of POM121 in bone-metastatic H460-BM subline and parental H460 cells. O-GlcNAcylated proteins were pulled down using <t>sWGA-beads.</t> Blots are representative of three independent experiments. E H460-BM cells expressing Myc (tag)-POM121 were treated with or without OGA inhibitor Thiamet G (TMG, 10 mM, 24 h). GlcNAc (+) indicates that sWGA-beads were pre-blocked with GlcNAc (500 mM, 24 h) prior to pulldown. Immunoprecipitation (IP) and immunoblots (IB) were performed using the indicated antibodies. Data are representative of three independent experiments. F H460-BM cells expressing Myc (tag)-POM121 and mutations were subjected to sWGA-beads pulldown or anti-Myc (tag)-IP. Immunoblots identified Ser199 as an O-GlcNAc modification site. Data are representative of three independent experiments. G Mapping the O-GlcNAcylated residue Ser199 on POM121 by liquid chromatography-tandem mass spectrometry (LC-MS/MS). H , I O-GlcNAcylation of POM121 at the Ser199 site in NSCLC promotes bone metastasis in nude mouse model. H Bioluminescence imaging of nude mice four weeks after intracardiac injection of H460-BM or H460-BM POM121-S199A cells (1 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document} × 10 5 cells/mouse). Data are represented as mean ± SEM; n = 6 mice/group, *** p < 0.001, unpaired t-test. I Representative H&E staining and tumor area quantifications of bone metastasis sections from mice in ( H ). Dashed lines demarcate tumor boundaries. Scale bar, 20 µm. Data are represented as mean ± SEM; **** p < 0.0001, unpaired t-test.
Goat Anti 451 Jo Urn Al Pr E P Ro F 22 Mouse Fitc Conjugated Antibody, supplied by Bethyl, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/goat anti 451 jo urn al pr e p ro f 22 mouse fitc conjugated antibody/product/Bethyl
Average 96 stars, based on 1 article reviews
goat anti 451 jo urn al pr e p ro f 22 mouse fitc conjugated antibody - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

93
Sino Biological rabbit anti 610 jo urn al pr e p ro f 32 human alpha galactosidase a polyclonal antibodies
A Protein levels of OGT, OGA and O-GlcNAc in bone-metastatic H460-BM subline and parental H460 cells. Blots are representative of three independent experiments. B Schematic of pulldown strategy to identify O-GlcNAc-modified proteins contributing to enhanced bone metastasis in H460-BM cells. C Left, significantly enriched ( p < 0.05) biological processes (GO analysis) for O-GlcNAc-modified proteins in H460-BM cells (top 10 pathways shown). Right, Enrichment of O-GlcNAcylation nucleoporins identified by mass spectrometry. D O-GlcNAcylation protein levels of POM121 in bone-metastatic H460-BM subline and parental H460 cells. O-GlcNAcylated proteins were pulled down using <t>sWGA-beads.</t> Blots are representative of three independent experiments. E H460-BM cells expressing Myc (tag)-POM121 were treated with or without OGA inhibitor Thiamet G (TMG, 10 mM, 24 h). GlcNAc (+) indicates that sWGA-beads were pre-blocked with GlcNAc (500 mM, 24 h) prior to pulldown. Immunoprecipitation (IP) and immunoblots (IB) were performed using the indicated antibodies. Data are representative of three independent experiments. F H460-BM cells expressing Myc (tag)-POM121 and mutations were subjected to sWGA-beads pulldown or anti-Myc (tag)-IP. Immunoblots identified Ser199 as an O-GlcNAc modification site. Data are representative of three independent experiments. G Mapping the O-GlcNAcylated residue Ser199 on POM121 by liquid chromatography-tandem mass spectrometry (LC-MS/MS). H , I O-GlcNAcylation of POM121 at the Ser199 site in NSCLC promotes bone metastasis in nude mouse model. H Bioluminescence imaging of nude mice four weeks after intracardiac injection of H460-BM or H460-BM POM121-S199A cells (1 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document} × 10 5 cells/mouse). Data are represented as mean ± SEM; n = 6 mice/group, *** p < 0.001, unpaired t-test. I Representative H&E staining and tumor area quantifications of bone metastasis sections from mice in ( H ). Dashed lines demarcate tumor boundaries. Scale bar, 20 µm. Data are represented as mean ± SEM; **** p < 0.0001, unpaired t-test.
Rabbit Anti 610 Jo Urn Al Pr E P Ro F 32 Human Alpha Galactosidase A Polyclonal Antibodies, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti 610 jo urn al pr e p ro f 32 human alpha galactosidase a polyclonal antibodies/product/Sino Biological
Average 93 stars, based on 1 article reviews
rabbit anti 610 jo urn al pr e p ro f 32 human alpha galactosidase a polyclonal antibodies - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

97
Proteintech 66009 1 ig jo urn al pr e p roo f
A Protein levels of OGT, OGA and O-GlcNAc in bone-metastatic H460-BM subline and parental H460 cells. Blots are representative of three independent experiments. B Schematic of pulldown strategy to identify O-GlcNAc-modified proteins contributing to enhanced bone metastasis in H460-BM cells. C Left, significantly enriched ( p < 0.05) biological processes (GO analysis) for O-GlcNAc-modified proteins in H460-BM cells (top 10 pathways shown). Right, Enrichment of O-GlcNAcylation nucleoporins identified by mass spectrometry. D O-GlcNAcylation protein levels of POM121 in bone-metastatic H460-BM subline and parental H460 cells. O-GlcNAcylated proteins were pulled down using <t>sWGA-beads.</t> Blots are representative of three independent experiments. E H460-BM cells expressing Myc (tag)-POM121 were treated with or without OGA inhibitor Thiamet G (TMG, 10 mM, 24 h). GlcNAc (+) indicates that sWGA-beads were pre-blocked with GlcNAc (500 mM, 24 h) prior to pulldown. Immunoprecipitation (IP) and immunoblots (IB) were performed using the indicated antibodies. Data are representative of three independent experiments. F H460-BM cells expressing Myc (tag)-POM121 and mutations were subjected to sWGA-beads pulldown or anti-Myc (tag)-IP. Immunoblots identified Ser199 as an O-GlcNAc modification site. Data are representative of three independent experiments. G Mapping the O-GlcNAcylated residue Ser199 on POM121 by liquid chromatography-tandem mass spectrometry (LC-MS/MS). H , I O-GlcNAcylation of POM121 at the Ser199 site in NSCLC promotes bone metastasis in nude mouse model. H Bioluminescence imaging of nude mice four weeks after intracardiac injection of H460-BM or H460-BM POM121-S199A cells (1 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document} × 10 5 cells/mouse). Data are represented as mean ± SEM; n = 6 mice/group, *** p < 0.001, unpaired t-test. I Representative H&E staining and tumor area quantifications of bone metastasis sections from mice in ( H ). Dashed lines demarcate tumor boundaries. Scale bar, 20 µm. Data are represented as mean ± SEM; **** p < 0.0001, unpaired t-test.
66009 1 Ig Jo Urn Al Pr E P Roo F, supplied by Proteintech, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/66009 1 ig jo urn al pr e p roo f/product/Proteintech
Average 97 stars, based on 1 article reviews
66009 1 ig jo urn al pr e p roo f - by Bioz Stars, 2026-03
97/100 stars
  Buy from Supplier

96
Proteintech dlat1 259 jo urn al pr e p roo f
A Protein levels of OGT, OGA and O-GlcNAc in bone-metastatic H460-BM subline and parental H460 cells. Blots are representative of three independent experiments. B Schematic of pulldown strategy to identify O-GlcNAc-modified proteins contributing to enhanced bone metastasis in H460-BM cells. C Left, significantly enriched ( p < 0.05) biological processes (GO analysis) for O-GlcNAc-modified proteins in H460-BM cells (top 10 pathways shown). Right, Enrichment of O-GlcNAcylation nucleoporins identified by mass spectrometry. D O-GlcNAcylation protein levels of POM121 in bone-metastatic H460-BM subline and parental H460 cells. O-GlcNAcylated proteins were pulled down using <t>sWGA-beads.</t> Blots are representative of three independent experiments. E H460-BM cells expressing Myc (tag)-POM121 were treated with or without OGA inhibitor Thiamet G (TMG, 10 mM, 24 h). GlcNAc (+) indicates that sWGA-beads were pre-blocked with GlcNAc (500 mM, 24 h) prior to pulldown. Immunoprecipitation (IP) and immunoblots (IB) were performed using the indicated antibodies. Data are representative of three independent experiments. F H460-BM cells expressing Myc (tag)-POM121 and mutations were subjected to sWGA-beads pulldown or anti-Myc (tag)-IP. Immunoblots identified Ser199 as an O-GlcNAc modification site. Data are representative of three independent experiments. G Mapping the O-GlcNAcylated residue Ser199 on POM121 by liquid chromatography-tandem mass spectrometry (LC-MS/MS). H , I O-GlcNAcylation of POM121 at the Ser199 site in NSCLC promotes bone metastasis in nude mouse model. H Bioluminescence imaging of nude mice four weeks after intracardiac injection of H460-BM or H460-BM POM121-S199A cells (1 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document} × 10 5 cells/mouse). Data are represented as mean ± SEM; n = 6 mice/group, *** p < 0.001, unpaired t-test. I Representative H&E staining and tumor area quantifications of bone metastasis sections from mice in ( H ). Dashed lines demarcate tumor boundaries. Scale bar, 20 µm. Data are represented as mean ± SEM; **** p < 0.0001, unpaired t-test.
Dlat1 259 Jo Urn Al Pr E P Roo F, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dlat1 259 jo urn al pr e p roo f/product/Proteintech
Average 96 stars, based on 1 article reviews
dlat1 259 jo urn al pr e p roo f - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

94
Proteintech glud1 polyclonal antibody 437 jo urn al pr e p roo f 22
A Protein levels of OGT, OGA and O-GlcNAc in bone-metastatic H460-BM subline and parental H460 cells. Blots are representative of three independent experiments. B Schematic of pulldown strategy to identify O-GlcNAc-modified proteins contributing to enhanced bone metastasis in H460-BM cells. C Left, significantly enriched ( p < 0.05) biological processes (GO analysis) for O-GlcNAc-modified proteins in H460-BM cells (top 10 pathways shown). Right, Enrichment of O-GlcNAcylation nucleoporins identified by mass spectrometry. D O-GlcNAcylation protein levels of POM121 in bone-metastatic H460-BM subline and parental H460 cells. O-GlcNAcylated proteins were pulled down using <t>sWGA-beads.</t> Blots are representative of three independent experiments. E H460-BM cells expressing Myc (tag)-POM121 were treated with or without OGA inhibitor Thiamet G (TMG, 10 mM, 24 h). GlcNAc (+) indicates that sWGA-beads were pre-blocked with GlcNAc (500 mM, 24 h) prior to pulldown. Immunoprecipitation (IP) and immunoblots (IB) were performed using the indicated antibodies. Data are representative of three independent experiments. F H460-BM cells expressing Myc (tag)-POM121 and mutations were subjected to sWGA-beads pulldown or anti-Myc (tag)-IP. Immunoblots identified Ser199 as an O-GlcNAc modification site. Data are representative of three independent experiments. G Mapping the O-GlcNAcylated residue Ser199 on POM121 by liquid chromatography-tandem mass spectrometry (LC-MS/MS). H , I O-GlcNAcylation of POM121 at the Ser199 site in NSCLC promotes bone metastasis in nude mouse model. H Bioluminescence imaging of nude mice four weeks after intracardiac injection of H460-BM or H460-BM POM121-S199A cells (1 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document} × 10 5 cells/mouse). Data are represented as mean ± SEM; n = 6 mice/group, *** p < 0.001, unpaired t-test. I Representative H&E staining and tumor area quantifications of bone metastasis sections from mice in ( H ). Dashed lines demarcate tumor boundaries. Scale bar, 20 µm. Data are represented as mean ± SEM; **** p < 0.0001, unpaired t-test.
Glud1 Polyclonal Antibody 437 Jo Urn Al Pr E P Roo F 22, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/glud1 polyclonal antibody 437 jo urn al pr e p roo f 22/product/Proteintech
Average 94 stars, based on 1 article reviews
glud1 polyclonal antibody 437 jo urn al pr e p roo f 22 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

99
LI-COR jo urn al pr e p roo f irdye 680rd goat anti rabbit igg secondary antibody
A Protein levels of OGT, OGA and O-GlcNAc in bone-metastatic H460-BM subline and parental H460 cells. Blots are representative of three independent experiments. B Schematic of pulldown strategy to identify O-GlcNAc-modified proteins contributing to enhanced bone metastasis in H460-BM cells. C Left, significantly enriched ( p < 0.05) biological processes (GO analysis) for O-GlcNAc-modified proteins in H460-BM cells (top 10 pathways shown). Right, Enrichment of O-GlcNAcylation nucleoporins identified by mass spectrometry. D O-GlcNAcylation protein levels of POM121 in bone-metastatic H460-BM subline and parental H460 cells. O-GlcNAcylated proteins were pulled down using <t>sWGA-beads.</t> Blots are representative of three independent experiments. E H460-BM cells expressing Myc (tag)-POM121 were treated with or without OGA inhibitor Thiamet G (TMG, 10 mM, 24 h). GlcNAc (+) indicates that sWGA-beads were pre-blocked with GlcNAc (500 mM, 24 h) prior to pulldown. Immunoprecipitation (IP) and immunoblots (IB) were performed using the indicated antibodies. Data are representative of three independent experiments. F H460-BM cells expressing Myc (tag)-POM121 and mutations were subjected to sWGA-beads pulldown or anti-Myc (tag)-IP. Immunoblots identified Ser199 as an O-GlcNAc modification site. Data are representative of three independent experiments. G Mapping the O-GlcNAcylated residue Ser199 on POM121 by liquid chromatography-tandem mass spectrometry (LC-MS/MS). H , I O-GlcNAcylation of POM121 at the Ser199 site in NSCLC promotes bone metastasis in nude mouse model. H Bioluminescence imaging of nude mice four weeks after intracardiac injection of H460-BM or H460-BM POM121-S199A cells (1 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document} × 10 5 cells/mouse). Data are represented as mean ± SEM; n = 6 mice/group, *** p < 0.001, unpaired t-test. I Representative H&E staining and tumor area quantifications of bone metastasis sections from mice in ( H ). Dashed lines demarcate tumor boundaries. Scale bar, 20 µm. Data are represented as mean ± SEM; **** p < 0.0001, unpaired t-test.
Jo Urn Al Pr E P Roo F Irdye 680rd Goat Anti Rabbit Igg Secondary Antibody, supplied by LI-COR, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/jo urn al pr e p roo f irdye 680rd goat anti rabbit igg secondary antibody/product/LI-COR
Average 99 stars, based on 1 article reviews
jo urn al pr e p roo f irdye 680rd goat anti rabbit igg secondary antibody - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

Image Search Results


A Protein levels of OGT, OGA and O-GlcNAc in bone-metastatic H460-BM subline and parental H460 cells. Blots are representative of three independent experiments. B Schematic of pulldown strategy to identify O-GlcNAc-modified proteins contributing to enhanced bone metastasis in H460-BM cells. C Left, significantly enriched ( p < 0.05) biological processes (GO analysis) for O-GlcNAc-modified proteins in H460-BM cells (top 10 pathways shown). Right, Enrichment of O-GlcNAcylation nucleoporins identified by mass spectrometry. D O-GlcNAcylation protein levels of POM121 in bone-metastatic H460-BM subline and parental H460 cells. O-GlcNAcylated proteins were pulled down using sWGA-beads. Blots are representative of three independent experiments. E H460-BM cells expressing Myc (tag)-POM121 were treated with or without OGA inhibitor Thiamet G (TMG, 10 mM, 24 h). GlcNAc (+) indicates that sWGA-beads were pre-blocked with GlcNAc (500 mM, 24 h) prior to pulldown. Immunoprecipitation (IP) and immunoblots (IB) were performed using the indicated antibodies. Data are representative of three independent experiments. F H460-BM cells expressing Myc (tag)-POM121 and mutations were subjected to sWGA-beads pulldown or anti-Myc (tag)-IP. Immunoblots identified Ser199 as an O-GlcNAc modification site. Data are representative of three independent experiments. G Mapping the O-GlcNAcylated residue Ser199 on POM121 by liquid chromatography-tandem mass spectrometry (LC-MS/MS). H , I O-GlcNAcylation of POM121 at the Ser199 site in NSCLC promotes bone metastasis in nude mouse model. H Bioluminescence imaging of nude mice four weeks after intracardiac injection of H460-BM or H460-BM POM121-S199A cells (1 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document} × 10 5 cells/mouse). Data are represented as mean ± SEM; n = 6 mice/group, *** p < 0.001, unpaired t-test. I Representative H&E staining and tumor area quantifications of bone metastasis sections from mice in ( H ). Dashed lines demarcate tumor boundaries. Scale bar, 20 µm. Data are represented as mean ± SEM; **** p < 0.0001, unpaired t-test.

Journal: Oncogene

Article Title: POM121 O-GlcNAcylation facilitates bone metastasis in non-small cell lung cancer through enhanced c-MYC nuclear import and ECM reprogramming

doi: 10.1038/s41388-026-03687-y

Figure Lengend Snippet: A Protein levels of OGT, OGA and O-GlcNAc in bone-metastatic H460-BM subline and parental H460 cells. Blots are representative of three independent experiments. B Schematic of pulldown strategy to identify O-GlcNAc-modified proteins contributing to enhanced bone metastasis in H460-BM cells. C Left, significantly enriched ( p < 0.05) biological processes (GO analysis) for O-GlcNAc-modified proteins in H460-BM cells (top 10 pathways shown). Right, Enrichment of O-GlcNAcylation nucleoporins identified by mass spectrometry. D O-GlcNAcylation protein levels of POM121 in bone-metastatic H460-BM subline and parental H460 cells. O-GlcNAcylated proteins were pulled down using sWGA-beads. Blots are representative of three independent experiments. E H460-BM cells expressing Myc (tag)-POM121 were treated with or without OGA inhibitor Thiamet G (TMG, 10 mM, 24 h). GlcNAc (+) indicates that sWGA-beads were pre-blocked with GlcNAc (500 mM, 24 h) prior to pulldown. Immunoprecipitation (IP) and immunoblots (IB) were performed using the indicated antibodies. Data are representative of three independent experiments. F H460-BM cells expressing Myc (tag)-POM121 and mutations were subjected to sWGA-beads pulldown or anti-Myc (tag)-IP. Immunoblots identified Ser199 as an O-GlcNAc modification site. Data are representative of three independent experiments. G Mapping the O-GlcNAcylated residue Ser199 on POM121 by liquid chromatography-tandem mass spectrometry (LC-MS/MS). H , I O-GlcNAcylation of POM121 at the Ser199 site in NSCLC promotes bone metastasis in nude mouse model. H Bioluminescence imaging of nude mice four weeks after intracardiac injection of H460-BM or H460-BM POM121-S199A cells (1 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\times$$\end{document} × 10 5 cells/mouse). Data are represented as mean ± SEM; n = 6 mice/group, *** p < 0.001, unpaired t-test. I Representative H&E staining and tumor area quantifications of bone metastasis sections from mice in ( H ). Dashed lines demarcate tumor boundaries. Scale bar, 20 µm. Data are represented as mean ± SEM; **** p < 0.0001, unpaired t-test.

Article Snippet: Protein A/G magnetic beads (Thermo, cat#88802), primary antibody (TABLE S ; validated for IP), species-matched IgG antibody (TABLE S ), or Succinylated Wheat Germ Agglutinin Agarose beads (sWGA-beads, VectorLabs, cat#AL-1023S) were pre-incubated with lysis buffer at room temperature for 4 h under rotation.

Techniques: Modification, Mass Spectrometry, Expressing, Immunoprecipitation, Western Blot, Residue, Liquid Chromatography, Liquid Chromatography with Mass Spectroscopy, Imaging, Injection, Staining

A Analysis of POM121 and OGT expression between parental H1299 and bone-metastatic H1299-BM sublines. Data representative of three experiments. B , C O-GlcNAcylation stabilizes POM121 in H1299-BM metastatic cells. B sWGA pulldown of O-GlcNAcylated proteins from H1299 and H1299-BM lysates, immunoblotted for POM121. C Analysis POM121 stability in H1299-BM transfected with OGT siRNAs and H1299 transfected with 3×Flag-OGT plasmid. Data representative of three experiments. D O-GlcNAcylated POM121 exhibited significantly attenuated binding affinity to TRIM21 in metastatic lineage. H1299 and H1299-BM cells treated with MG132 (25 nM, 24 h). Cell lysates IP with anti-POM121 and immunoblotted for TRIM21 and ubiquitin. Data representative of three experiments. E Enhanced nuclear c-MYC accumulation in metastatic cells. Immunoblots of c-MYC levels in the nucleoplasm and cytoplasm of H1299 cells and H1299-BM cells. HSP90 and UAP56 served as fractionation controls. Data representative of three experiments. F Left, ECM-related genes mRNA levels were analyzed by RT-qPCR between H1299 and H1299-BM cells. (mean ± SEM; n = 3; unpaired t-test). Right, Analysis of PI3K-AKT-mTOR pathway activation (p-PI3K/PI3K, p-AKT/AKT, p-mTOR/mTOR) between H1299 and H1299-BM cells. Data representative of three experiments. G Pan-cancer analysis showed that POM121 was highly expressed in NSCLC. (TCGA data; * p < 0.05, ** p < 0.01, *** p < 0.001). H High POM121 and c-MYC co-expression correlates with poor NSCLC prognosis. Kaplan-Meier overall survival analysis of 2166 NSCLC patients from TCGA, stratified by high/low mRNA expression of POM121 (log-rank test, p < 0.05). I Significantly elevated POM121 and c-MYC expression in bone metastatic lesions versus primary lung lesions of LUAD patients with bone metastasis. Data derived from the GSE225208 dataset (bulk RNA-seq; n = 20 primary lung lesions vs. n = 7 bone metastatic lesions, unpaired t -test, *** p < 0.001, **** p < 0.0001).

Journal: Oncogene

Article Title: POM121 O-GlcNAcylation facilitates bone metastasis in non-small cell lung cancer through enhanced c-MYC nuclear import and ECM reprogramming

doi: 10.1038/s41388-026-03687-y

Figure Lengend Snippet: A Analysis of POM121 and OGT expression between parental H1299 and bone-metastatic H1299-BM sublines. Data representative of three experiments. B , C O-GlcNAcylation stabilizes POM121 in H1299-BM metastatic cells. B sWGA pulldown of O-GlcNAcylated proteins from H1299 and H1299-BM lysates, immunoblotted for POM121. C Analysis POM121 stability in H1299-BM transfected with OGT siRNAs and H1299 transfected with 3×Flag-OGT plasmid. Data representative of three experiments. D O-GlcNAcylated POM121 exhibited significantly attenuated binding affinity to TRIM21 in metastatic lineage. H1299 and H1299-BM cells treated with MG132 (25 nM, 24 h). Cell lysates IP with anti-POM121 and immunoblotted for TRIM21 and ubiquitin. Data representative of three experiments. E Enhanced nuclear c-MYC accumulation in metastatic cells. Immunoblots of c-MYC levels in the nucleoplasm and cytoplasm of H1299 cells and H1299-BM cells. HSP90 and UAP56 served as fractionation controls. Data representative of three experiments. F Left, ECM-related genes mRNA levels were analyzed by RT-qPCR between H1299 and H1299-BM cells. (mean ± SEM; n = 3; unpaired t-test). Right, Analysis of PI3K-AKT-mTOR pathway activation (p-PI3K/PI3K, p-AKT/AKT, p-mTOR/mTOR) between H1299 and H1299-BM cells. Data representative of three experiments. G Pan-cancer analysis showed that POM121 was highly expressed in NSCLC. (TCGA data; * p < 0.05, ** p < 0.01, *** p < 0.001). H High POM121 and c-MYC co-expression correlates with poor NSCLC prognosis. Kaplan-Meier overall survival analysis of 2166 NSCLC patients from TCGA, stratified by high/low mRNA expression of POM121 (log-rank test, p < 0.05). I Significantly elevated POM121 and c-MYC expression in bone metastatic lesions versus primary lung lesions of LUAD patients with bone metastasis. Data derived from the GSE225208 dataset (bulk RNA-seq; n = 20 primary lung lesions vs. n = 7 bone metastatic lesions, unpaired t -test, *** p < 0.001, **** p < 0.0001).

Article Snippet: Protein A/G magnetic beads (Thermo, cat#88802), primary antibody (TABLE S ; validated for IP), species-matched IgG antibody (TABLE S ), or Succinylated Wheat Germ Agglutinin Agarose beads (sWGA-beads, VectorLabs, cat#AL-1023S) were pre-incubated with lysis buffer at room temperature for 4 h under rotation.

Techniques: Expressing, Transfection, Plasmid Preparation, Binding Assay, Ubiquitin Proteomics, Western Blot, Fractionation, Quantitative RT-PCR, Activation Assay, Derivative Assay, RNA Sequencing